Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy

Cancer Gene Therapy

Volumn 12, Issue 3, 2005, Pages 276-283

  Wang, Dongfang ^a   Ruan, Hangjun ^a   Hu, Lily ^a   Lamborn, Kathleen R ^a   Kong, Eileen L ^a   Rehemtulla, Alnawaz ^b   Deen, Dennis F ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NONE   (United States)

Author keywords

Bystander effect; Cytosine deaminase; Glioblastoma; Hypoxia

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1; PRODRUG; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; BYSTANDER EFFECT; CANCER THERAPY; CATALYST; CELL KILLING; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; GENE CONSTRUCT; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIA; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN VIRUS 40; SOLID TUMOR; TUMOR CELL; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; CYTOSINE DEAMINASE; ENHANCER ELEMENTS (GENETICS); ERYTHROPOIETIN; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; PRODRUGS; SIMIAN VIRUS 40; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR STEM CELL ASSAY; YEASTS;

MAMMALIA;

EID: 14644396577     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700748     Document Type: Article

References (40)

1. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449-6465.
2. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-276.
3. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys. 1994;29:427-431.
4. Kayama T, Yoshimoto T, Fujimoto S, Sakurai Y. Intra-tumoral oxygen pressure in malignant brain tumor. J Neurosurg. 1991;74:55-59.
5. Brahimi-Horn C, Berra E, Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trendy Cell Biol. 2001;11:S32-S36.
6. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F Cain Memorial Award lecture. Cancer Res. 1999;59:5863-5870.
7. Ruan H, Su H, Hu L, et al. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia. 2001;3:255-263.
8. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
9. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 2000;88:2606-2618.
10. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8:S62-S67.
11. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18-32.
12. Seagroves TN, Ryan HE, Lu H, et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol. 2001;21:3436-3444.
13. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med. 2001;7:345-350.
14. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for 02 sensing. Science. 2001;292:464-468.
15. Min JH, Yang H, Ivan M, et al. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science. 2002;296:1886-1889.
16. 2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
17. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157:411-421.
18. Zhong H, DeMarzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830-5835.
19. Minchenko A, Leshchinsky I, Opentanova I, et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6- bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem. 2002;277:6183-6187.
20. Ruan H, Wang J, Hu L, et al. Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX. Neoplasia. 1999;1:431-437.
21. Hassouna I, Wickert H, Zimmermann M, Gillardon F. Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment of mice. Neurosci Lett. 1996;204:85-88.
22. Pastorino JG, Chen ST, Tafani M, et al. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem. 1998;273:7770-7775.
23. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 1997;385:637-640.
24. Corban-Wilhelm H, Hull WE, Becker G, et al. Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy. Gene Ther. 2002;9:1564-1575.
25. Heidelberger C, Danenberg PV, Moran RG. Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol. 1983;54:58-119.
26. Hamstra DA, Rice DJ, Fahmy S, et al. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther. 1999;10:1993-2003.
27. Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999;59:1417-1421.
28. Khil MS, Kim JH, Mullen CA, et al. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res. 1996;2:53-57.
29. Vauthey JN, Marsh Rde W, Cendan JC, et al. Arterial therapy of hepatic colorectal metastases. Br J Surg. 1996;83:447-455.
30. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med. 1997;3:515-520.
31. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the 'hypoxic fraction' in determining tumor response to fractionated radiotherapy. Radiat Res. 1997;147:541-550.
32. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 2000;60:2936-2941.
33. Shibata T, Giaccia AJ, Brown JM. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia. 2002;4:40-48.
34. Cao YJ, Shibata T, Rainov NG. Hypoxia-inducible transgene expression in differentiated human NT2N neurons - a cell culture model for gene therapy of postischemic neuronal loss. Gene Ther. 2001;8:1357-1362.
35. Gupta N, Vij R, Haas-Kogan DA, et al. Cytogenetic damage and the radiation-induced G1-phase checkpoint. Radiat Res. 1996;145:289-298.
36. Lawrence TS, Rehemtulla A, Ng EY, et al. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res. 1998;58:2588-2593.
37. Erbs P, Exinger F, Jund R. Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans. Curr Genet. 1997;31:1-6.
38. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 1987;15:8125-8148.
39. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269:23757-23763.
40. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000;60:3813-3822.